<DOC>
	<DOC>NCT01447654</DOC>
	<brief_summary>Objective The objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM). Design The study is a randomized, placebo‐controlled, double‐blinded trial. The follow‐up period is 12 months. 130 patients with HCM will be included in predefined subgroups. Genotype positive relatives with borderline hypertrophy (&gt; 13 mm) will also be included. Data on individuals with borderline hypertrophy will be analysed separately from the rest of the cohort. Primary outcome Ventricular hypertrophy assessed as left ventricular mass and maximal wall thickness.</brief_summary>
	<brief_title>Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Hypertrophic cardiomyopathy &gt; 18 years Sinus rhythm EF &lt; 50 % Treatment with RASinhibitor Contraindications to losartan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hypertrophic cardiomyopathy</keyword>
	<keyword>Hypertrophic obstructive cardiomyopathy</keyword>
	<keyword>Hypertrophy</keyword>
	<keyword>Losartan</keyword>
	<keyword>Angiotensin II receptor antagonist</keyword>
</DOC>